A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity

Objective: Calprotectin is a granulocyte and monocyte cytosolic protein that is released during activation of these cells. The plasma level of calprotectin is raised in various inflammatory conditions and correlates with disease activity in a wide range of rheumatic diseases. We wanted to investigat...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of rheumatology 2005-04, Vol.34 (2), p.125-128
Main Authors: Brun, J. G., Madland, T. M., Gran, J. T., Myklebust, G.
Format: Article
Language:English
Subjects:
Acute-Phase Reaction - blood
Aged
Anti-Inflammatory Agents - therapeutic use
Biological and medical sciences
Biomarkers - blood
Blood Sedimentation
Diseases of the osteoarticular system
Female
Giant Cell Arteritis - blood
Giant Cell Arteritis - diagnosis
Humans
Inflammatory joint diseases
Leukocyte L1 Antigen Complex - blood
Male
Medical sciences
Polymyalgia Rheumatica - blood
Polymyalgia Rheumatica - diagnosis
Polymyalgia Rheumatica - drug therapy
Prednisolone - therapeutic use
Prospective Studies
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Calprotectin is a granulocyte and monocyte cytosolic protein that is released during activation of these cells. The plasma level of calprotectin is raised in various inflammatory conditions and correlates with disease activity in a wide range of rheumatic diseases. We wanted to investigate whether calprotectin may be useful as a measure of disease activity in polymyalgia rheumatica (PMR) and temporal arteritis (TA). Methods: Forty-seven patients with PMR and or TA were followed up to 3 years in a prospective longitudinal design. Plasma calprotectin was correlated with acute phase parameters, erythrocyte sedimentation rate (ESR), and peroral steroid usage before start of treatment and at four subsequent time intervals. Results: Thirty-three patients had PMR, 10 had TA, and four had both diagnoses. Calprotectin was highly correlated with the acute phase parameters and ESR during the study period. Calprotectin was significantly decreased after start of treatment with oral prednisolone, and correlated with the daily dosage of prednisolone (r = 0.36, p
ISSN:0300-9742
1502-7732
DOI:10.1080/03009740410009931